EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection

Pajaree Chariyavilaskul iD, Nantaporn Prompila iD, Supeecha Wittayalertpanya iD, Sookruethai Lekhyananda, Wisit Prasithsirikul iD, Thananda Trakarnvanich iD, Somboon Jeenapongsa, Paweena Susantitaphong iD, Stephen Kerr iD, Anchalee Avihingsanon iD, Pisit Tangkijvanich iD, Kearkiat Praditpornsilpa iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Pajaree Chariyavilaskul und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Sofosbuvir, Carbamates, Renal Dialysis, Heterocyclic Compounds, 4 or More Rings. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Thailand Science Research and Innovation Fund, Chulalongkorn University, The Kidney Foundation of Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sofosbuvir/Velpatasvir (SOF/VEL) is a combination drug used for chronic hepatitis C (HCV) infection. However, limited information exists regarding the pharmacokinetics of SOF/VEL and its metabolites in hemodialysis patients. We conducted a prospective investigation of the pharmacokinetic parameters of SOF/VEL after a single dose of SOF/VEL (400/100 mg) on days with and without dialysis in 12 Thai hemodialysis patients with chronic HCV infection, who had been undergoing hemodialysis for a duration of 0.5–20 years. Blood samples were collected before dose (0) and 0.5, 1.0, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, and 12.0 h after dose. Dialysate samples were also collected before dose (0) and 1.0, 2.0, 3.0, and 4.0 h after dose. Plasma and dialysate samples were quantified for SOF and its metabolite, GS‐331007, and VEL concentrations using a fully validated LCMS technique. In addition, a preliminary efficacy study was conducted using the proposed SOF/VEL dose reduction regimen in all patients. No differences in SOF/VEL PK parameters between on‐ and off‐dialysis studies. On the contrary, GS‐331007 exhibited a 30% reduction in the area under the plasma concentration–time curve from time 0 to 24 h (AUC 0‐24h ) on dialysis days compared with non‐dialysis days (AUC 0‐24h ratio 0.68 vs. 1.04, respectively). The dialysis clearance of SOF and GS‐331007 was 9.35 (8.72–15.11) and 8.89 (8.52–14.07) mL/min, respectively. Subsequently, an alternate‐day regimen of SOF/VEL (400/100 mg) was administered for 12 weeks, resulting in an undetectable plasma HCV viral load without side effects. Further clinical studies are warranted to validate the efficacy and safety of our proposed dose reduction regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SofosbuvirCarbamatesRenal DialysisHeterocyclic Compounds, 4 or More RingsHepatitis C, ChronicAntiviral AgentsDrug CombinationsDrug Administration ScheduleHumansMaleMiddle AgedFemaleProspective StudiesAgedAdultTreatment OutcomeHepacivirusBenzimidazolesBenzopyrans

Substanzen

SofosbuvirCarbamatesHeterocyclic Compounds, 4 or More RingsAntiviral Agentssofosbuvir-velpatasvir drug combinationDrug CombinationsvelpatasvirBenzimidazolesBenzopyrans

Autor:innen und Institutionen

  • Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Chula Pharmacokinetic Research Center, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • The Kidney Foundation of Thailand, Bangkok, Thailand.
  • Department of Disease Control, Bamrasnaradura Infectious Institute, Ministry of Public Health, Thailand.
  • Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.

ORCID-Profile: Pajaree Chariyavilaskul, Nantaporn Prompila, Supeecha Wittayalertpanya, Wisit Prasithsirikul, Thananda Trakarnvanich, Paweena Susantitaphong, Stephen Kerr, Anchalee Avihingsanon, Pisit Tangkijvanich, Kearkiat Praditpornsilpa

Förderung

  • Thailand Science Research and Innovation Fund, Chulalongkorn University
  • The Kidney Foundation of Thailand

Zitieren

APA

Chariyavilaskul, P., Prompila, N., Wittayalertpanya, S., Lekhyananda, S., Prasithsirikul, W., Trakarnvanich, T., Jeenapongsa, S., Susantitaphong, P., Kerr, S., Avihingsanon, A., Tangkijvanich, P., & Praditpornsilpa, K. (2024). Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection. Clinical and Translational Science. https://doi.org/10.1111/cts.13884

Vancouver

Chariyavilaskul P, Prompila N, Wittayalertpanya S, Lekhyananda S, Prasithsirikul W, Trakarnvanich T, et al. Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection. Clinical and Translational Science. 2024. doi:10.1111/cts.13884

BibTeX
@article{Chariyavilaskul2024,
  author = {Chariyavilaskul, Pajaree and Prompila, Nantaporn and Wittayalertpanya, Supeecha and Lekhyananda, Sookruethai and Prasithsirikul, Wisit and Trakarnvanich, Thananda and Jeenapongsa, Somboon and Susantitaphong, Paweena and Kerr, Stephen and Avihingsanon, Anchalee and Tangkijvanich, Pisit and Praditpornsilpa, Kearkiat},
  title = {Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13884}
}
Kostenlos starten →